



ACCURIDS

AFO + IDMP-O:

Connecting pharma data across the entire value chain with a network of interoperable industry ontologies

Heiner Oberkampf - ACCURIDS





Shortage Monitoring

Unique Identification of Medicinal Products





Supply Chain Analytics

Data-Driven Submissions



We need a shared data language to solve global challenges together



Patient Safety

Personalized Medicine




Cross-boarder Prescriptions

Indications & Trials



AI & Digital Transformation




ISO IDMP Standards




ISO IDMP

ISO standards for unique identification and exchange of information about medicinal products to improve patient safety and facilitate the data-driven collaboration between authorities, healthcare professionals, and pharmaceutical companies.


IDMP Ontology: shared data language for medicinal products Pharma internally ... and across the industry



IDMP landscape is a complex one...



Source: EMA



- 1. Our approach to building IDMP-O becomes an ISO Technical Specification
- 3. Release of IDMP-O v1.0 in January 2024

 Open-source and ready for production implementation
- 4. Successful collaboration with IDMP stakeholders

 Tested IDMP-O with data from

 MedDICINES

 MedDICI
- 5. Bio-IT World Conference Innovative Practices Award 2024 for Pre-Competitive Collaboration



























WHODrug as a Knowledge Graph within the IDMP Ontology

Idea: Support current and new use cases for WHODrug with IDMP within pharma by seamless integration with other IDMP-O aligned data sources (connecting to e.g., pharma, EMA SPOR, FDA GSRS)









precisionFDA Regulatory Information Service Module FDA-Industry Research Collaboration Agreement (Public-Private Partnership)

Vada A. Perkins
VP/Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim
PRISM Principal Investigator

April 2024













Our Trajectory & Outlook

Phase 4 and Beyond: Production & Sustainability Planning for 2025

Phase 3:

Pharma Implementation & **Industry Adoption**

2024

- Focus on production implementations
- Collaboration with Health Authorities
- > Interoperability with other domains
- Opening to vendors and consultancies
- Introduction of Open Core Model
- Release v1.1 in April

Phase 2:

Build IDMP-O 1.0 for Production Use

Released in

2023

January 2024

IDMP-O MVP

Phase 1:

2022 Apr-Oct

Global Governance & Data Standards



Infrastructure as a Service

Pistoia Alliance is building a sustainable, coordinated, ontology project portfolio with IDMP-O at it's core.

Connecting to Allotrope®
Foundation Ontology (AFO)
with many bridge concepts
through IDMP-O and CMC
Process Ontology



AFO + IDMP-O: Bridge Concepts & Use Cases

Use Cases related to ...

1. Stability and shelf-live data

- → Better clinical supply
- → Drug shortage monitoring

2. PQ CMC - Quality data

- → data-driven submission
- → process optimization

3. Materials & batches

- → material alternatives (ESG)
- → material supplier alternatives
- → batch release

4. Product labeling

→ update packaged product labels in manufacturing

5. Substance

→ globally unique identification

6. Lab tests and units

→ bridge clinical, lab, regulatory

7. ... → ...



ACCURIDS










Q

8

[•]

\$
















Q


*

:=

U

1









Q Search





powered by **ACCURIDS**







주




Q


B

[•]



- + L2 PhP of Bevacizumab, 25.00 mg/ml
- + L3 PhP of Bevacizumab, Concentrate for s
- + L4 PhP of Bevacizumab, 25.00 mg/ml, Co
- + Goserelin acetate
- + Ibuprofen
- + Ibuprofen sodium
- + Paracetamol













































- + L1 PhP of Bevacizumab
- + L2 PhP of Bevacizumab, 25.00 mg/ml
- + L3 PhP of Bevacizumab, Concentrate for solu
- L4 PhP of Bevacizumab, 25.00 mg/ml, Conce

Abevmy (MedProd)

Avastin (MedProd)

Avastin (MedProd)

Avastin (MedProd)

Aybintio (MedProd)

Onbevzi (MedProd)

Vegzelma (MedProd)

- + Goserelin acetate
- + Ibuprofen
- + Ibuprofen sodium
- + Paracetamol

Avastin (MedProd)





Label	Avastin (MedProd)
URI	https://who-umc.org/whodrug-global/mpid/3182215
type	medicinal product
comprises	L4 PhP of Bevacizumab, 25.00 mg/ml, Concentrate for solution for infusion, Injection
hasPhPIDLevel1	L1 PhP of Bevacizumab
hasPhPIDLevel2	L2 PhP of Bevacizumab, 25.00 mg/ml
hasPhPIDLevel3	L3 PhP of Bevacizumab, Concentrate for solution for infusion
hasPhPIDLevel4	L4 PhP of Bevacizumab, 25.00 mg/ml, Concentrate for solution for infusion, Injection
is identified by	3182215
plays role	Avastin in Brazil by Roche (AMP)



what is the active ingredient of avastin?

//CCURIDS

V

Accurids

The active ingredient of Avastin is Bevacizumab 1 . Bevacizumab is an anti-VEGF humanized murine monoclonal antibody that inhibits VEGF receptors and helps to prevent pathologic angiogenesis 1 .

Sources

1. Bevacizumab - Accurids ← ←²



Heiner Oberkampf

where is avastin registered? by which company?



Accurids

Avastin is registered in various countries, and some of the registrations include:

- 1. Avastin in Norway by Roche¹.
- 2. Avastin in the United States of America by Genentech².

These registrations indicate that the company responsible for Avastin is Roche, and its subsidiary Genentech is responsible for the product in the USA.

Sources

- 1. Avastin in Norway by Roche Accurids ←
- 2. Avastin in United States of America by Genentech Accurids ←

Standards-based knowledge graphs enable AI-powered chats based on facts with data references

Join us and get involved



Contact Us
idmpo@PistoiaAlliance.org

Join the Initiative
The IDMP Ontology

